BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Taugner J, Käsmann L, Eze C, Rühle A, Tufman A, Reinmuth N, Duell T, Belka C, Manapov F. Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients. Invest New Drugs 2021;39:1189-96. [PMID: 33704621 DOI: 10.1007/s10637-021-01091-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Ma J, Li H, Cao Z, Sha J, Sun R, He H, Wan Y, Li Y, Li T, Ren B. Solid-liquid phase equilibrium of Nintedanib in ten pure solvents: Determination, thermodynamic analysis, model correlation and molecular simulation. The Journal of Chemical Thermodynamics 2021;163:106595. [DOI: 10.1016/j.jct.2021.106595] [Reference Citation Analysis]
2 Kubo N, Kobayashi D, Iwanaga M, Matsuura M, Higuchi K, Eishima J, Muramatsu H, Okano N, Shioya M, Onishi M, Aoki T, Oike T, Ohno T; Gunma Society for Radiation Oncology (GUSTRO). Radiotherapy Patterns of Care for Locally-advanced Non-small Cell Lung Cancer in the Pre- and Post-durvalumab Era: A Region-wide Survey in a Japanese Prefecture. J Radiat Res 2021:rrab116. [PMID: 34970980 DOI: 10.1093/jrr/rrab116] [Reference Citation Analysis]
3 Fitzpatrick O, Naidoo J. Immunotherapy for Stage III NSCLC: Durvalumab and Beyond. Lung Cancer (Auckl) 2021;12:123-31. [PMID: 34754256 DOI: 10.2147/LCTT.S305466] [Reference Citation Analysis]
4 Kauffmann-Guerrero D, Taugner J, Eze C, Käsmann L, Li M, Tufman A, Manapov F. Clinical Management and Outcome of Grade III Pneumonitis after Chemoradioimmunotherapy for Inoperable Stage III Non-Small Cell Lung Cancer-A Prospective Longitudinal Assessment. Diagnostics (Basel) 2021;11:1968. [PMID: 34829315 DOI: 10.3390/diagnostics11111968] [Reference Citation Analysis]
5 Yamamoto T, Tsukita Y, Katagiri Y, Matsushita H, Umezawa R, Ishikawa Y, Takahashi N, Suzuki Y, Takeda K, Miyauchi E, Saito R, Katsuta Y, Kadoya N, Jingu K. Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice. BMC Cancer 2022;22:364. [PMID: 35379201 DOI: 10.1186/s12885-022-09354-1] [Reference Citation Analysis]
6 A K, H S, W H, As F, P WP, A R. Consolidative durvalumab outcomes in stage III non-small cell lung cancer in a multi-centre study. Cancer Treat Res Commun 2021;29:100496. [PMID: 34864586 DOI: 10.1016/j.ctarc.2021.100496] [Reference Citation Analysis]
7 Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, Vansteenkiste JF, Garassino MC, Hui R, Quantin X, Rimner A, Wu YL, Özgüroğlu M, Lee KH, Kato T, de Wit M, Kurata T, Reck M, Cho BC, Senan S, Naidoo J, Mann H, Newton M, Thiyagarajah P, Antonia SJ. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol 2022;:JCO2101308. [PMID: 35108059 DOI: 10.1200/JCO.21.01308] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 22.0] [Reference Citation Analysis]